title: Reduced WWOX protein expression in human astrocytoma.
abstract: The WW domain-containing oxidoreductase (WWOX) functions as a tumor suppressor by interacting with various proteins in numerous important signaling pathways. WWOX silencing via homozygous deletion of its locus and/or promoter hypermethylation has been observed in various human cancers. However, the relationship between WWOX and tumors in the central nervous system has not been fully explored. In this study, the expression levels of WWOX protein in astrocytomas from 38 patients with different tumor grades were retrospectively analyzed by immunohistochemical staining. The results showed that 19 (50.0%) samples had highly reduced WWOX protein expression when compared with normal controls, while 14 (36.8%) and five (13.2%) cases exhibited moderate and mild decreases in WWOX expression, respectively. Reduction of the expression of WWOX protein correlated with patient age, supra-tentorial localization of the tumor and severity of the symptoms. Furthermore, loss of WWOX expression inversely correlated with survival time. No significant correlation was observed between the loss of WWOX expression and the gender of patients or the difference in pre-operative and post-operative karnofsky performance status scores. Surprisingly, there was no significant correlation between the loss of WWOX protein expression and overall tumor grades. Nevertheless, it was found that 63.6% (7/11) of the grade II astrocytomas had highly reduced WWOX expression and 36.4% (4/11) showed moderately reduced WWOX expression, while none of the samples exhibited mild reductions. Similar results were also found in grade III astrocytomas. The results from this small-size sample pilot study suggest that the loss of WWOX expression may be an early event in the pathogenesis of human astrocytoma.
authors.affiliation: School of Medicine, Poznan University, Poznan, Poland.
authors.forename: William
authors.initials: W
authors.lastname: Winardi
authors.forename: Cheng-Yu
authors.initials: CY
authors.lastname: Tsai
authors.forename: Wan-Tzu
authors.initials: WT
authors.lastname: Chen
authors.forename: Hung-Pei
authors.initials: HP
authors.lastname: Tsai
authors.forename: Chia-Li
authors.initials: CL
authors.lastname: Chung
authors.forename: Jong-Kim
authors.initials: JK
authors.lastname: Loh
authors.forename: Chee-Yin
authors.initials: CY
authors.lastname: Chai
authors.forename: Aij-Lie
authors.initials: AL
authors.lastname: Kwan
mesh_terms: D000328:Adult; D001254:Astrocytoma / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D014408:Biomarkers, Tumor / Q000032:analysis*; D001932:Brain Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D010088:Oxidoreductases / Q000096:biosynthesis*; D012189:Retrospective Studies; D025521:Tumor Suppressor Proteins / Q000096:biosynthesis*; D000074584:WW Domain-Containing Oxidoreductase
chemical_list: D014408:Biomarkers, Tumor; D025521:Tumor Suppressor Proteins; D010088:Oxidoreductases; D000074584:WW Domain-Containing Oxidoreductase; C486071:WWOX protein, human
keywords: WWOX expression; astrocytoma; immunohistochemical staining; tumor suppressor